Egetis Therapeutics Announces U.S. Launch of EMCITATE® for Patients with MCT8 Deficiency

* EMCITATE is the first and only FDA-approved treatment for peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency in the United States

Egetis RareLink™, the dedicated patient support program, provides access assistance, education and care coordination in partnership with PANTHERx® Rare Pharmacy STOCKHOLM, SWEDEN, Sept. 27, 2026 – (GlobeNewswire) Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockholm: EGTX), a commercial-stage pharmaceutical company focused on developing and delivering innovative therapies for patients with rare diseases, today announced the commercial availability of EMCITATE® (tiratricol), ahead of anticipated timelines following U.S. Food and Drug Administration (FDA) approval on September 28, 2026. EMCITATE is indicated for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency, also known as Allan-Herndon-Dudley syndrome. It is the first and only FDA-approved treatment for MCT8 deficiency in the United States. EMCITATE is not recommended for the treatment of primary hypothyroidism. “Launching EMCITATE in the United States ahead of our anticipated timelines marks an important milestone for people living with MCT8 deficiency, their families and everyone who has worked toward bringing an approved treatment to this community,” said Nicklas Westerholm, chief executive officer of Egetis Therapeutics. “Following FDA approval, our focus is now on building on this momentum and helping eligible patients access treatment as quickly as possible. We remain deeply committed to the MCT8 deficiency community and grateful to the patients, families, clinicians, investigators and advocacy organizations that continue to support these efforts.” MCT8 deficiency is a rare, devastating, life-limiting, X-linked disorder caused by pathogenic mutations in the SLC16A2 gene. These mutations impair the function of MCT8, a critical cell-surface thyroid hormone transporter responsible for thyroid hormone transport in specific cells, including in the brain. The resulting disruption of thyroid hormone signaling leads to severe neurodevelopmental impairment and persistent peripheral thyrotoxicosis. Patients with MCT8 deficiency have a reported median life expectancy of approximately 35 years. To support the U.S. launch, Egetis has established Egetis RareLink, its dedicated patient support program, in partnership with PANTHERx Rare Pharmacy. The program is designed to help eligible patients, caregivers and health care professionals navigate medication access, education, care coordination and ongoing treatment services. Through Egetis RareLink, the Company aims to provide dedicated support and help eligible patients access EMCITATE. Patients and caregivers can learn more by calling 1-844-4EGETIS (1-844-434-3847) or go to EMCITATE.com. About EMCITATE® EMCITATE (tiratricol) is a thyroid hormone receptor agonist indicated for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan–Herndon–Dudley syndrome). Limitation of use: EMCITATE is not recommended for the treatment of primary hypothyroidism. About MCT8 Deficiency Monocarboxylate transporter 8 (MCT8) deficiency, also known as Allan–Herndon–Dudley syndrome (AHDS), is a rare, devastating, life-limiting, X-linked disorder caused by pathogenic mutations in the SLC16A2 gene. These mutations impair the function of MCT8, a critical cell-surface thyroid hormone transporter responsible for thyroid hormone transport in specific cells, including in the brain. Patients experience insufficient thyroid hormone activity in the central nervous system and excessive exposure to the active thyroid hormone triiodothyronine (T3) in peripheral tissues. This results in severe neurodevelopmental impairment and persistent peripheral thyrotoxicosis. Elevated T3 concentrations in peripheral tissues can result in a chronic hypermetabolic state affecting multiple organs, including the heart, muscles, liver and kidneys. Clinical manifestations may include failure to thrive, cardiovascular strain, muscle wasting, metabolic imbalance and increased susceptibility to infections. These systemic consequences are believed to contribute significantly to the increased morbidity and premature mortality associated with the disorder. Patients with MCT8 deficiency have a reported median life expectancy of approximately 35 years. For more information about MCT8 deficiency, visit MCT8deficiency.com or LifewithMCT8deficiency.com. Important Safety Information BOXED WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Contraindications: EMCITATE is contraindicated in patients with primary hyperthyroidism. Warnings and precautions

Thyrotoxicosis: Signs and symptoms of thyrotoxicosis, including increased heart rate, elevated blood pressure, diarrhea, hyperhidrosis, irritability, insomnia and nightmares, have occurred during treatment initiation and dose titration. Monitor patients and adjust the EMCITATE dose as indicated.

Laboratory test interference for T3 measurement: Tiratricol can cross-react with immunoassays for T3, leading to unreliable T3 results and overestimation of T3. Adverse reactions: The most common adverse reactions (≥5%) are diarrhea, vomiting, rash and hyperhidrosis. To report suspected adverse reactions, contact Egetis Therapeutics US Inc. at 1-844-4EGETIS (1-844-434-3847) or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Please see the full Prescribing Information: https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information. pdf About Egetis Therapeutics Egetis Therapeutics is a commercial-stage pharmaceutical company focused on developing and delivering innovative therapies for patients with rare diseases with significant unmet medical need. Combining scientific and clinical expertise with integrated late-stage development, regulatory and commercial capabilities, and manufacturing expertise, Egetis is committed to delivering treatments and dedicated support to underserved patient communities. The Company’s lead product, EMCITATE® (tiratricol), is the first and only approved treatment for MCT8 deficiency, a rare and life-shortening genetic disorder, with marketing authorizations in the European Union and the United States. Headquartered in Stockholm, Sweden, with operations in the U.S. and Europe, Egetis is building a sustainable global rare disease company. For more information, visit egetis.com and follow the Company on LinkedIn. About PANTHERx Rare PANTHERx Rare makes rare disease care more personalized and less overwhelming by focusing on each patient and each therapy. PANTHERx experts develop relationships with patients, prescribers and pharmaceutical partners, serving as trusted advocates to support collaboration and care. Founded in Pittsburgh, Pennsylvania, in 2011, PANTHERx has grown into the largest independent rare pharmacy in the U.S. PANTHERx is licensed in all 50 states and U.S. territories and was the first national pharmacy to achieve dual rare disease accreditations from the Accreditation Commission for Health Care (ACHC) and the Utilization Review Accreditation Commission (URAC). PANTHERx received the 2026 MMIT Patient Choice Award for patient satisfaction, marking its ninth win. For more information, visit www.pantherxrare.com. For further information, please contact: Nicklas Westerholm, CEO +46 (0) 733 542 062 nicklas.westerholm@egetis.com Karl Hård, Head of Investor Relations, Communications & Business Development +46 (0) 733 011 944 karl.hard@egetis.com Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the commercialization and availability of EMCITATE® (tiratricol) in the United States, the timing and outcome of potential monetization of the Rare Pediatric Disease Priority Review Voucher, the expected capabilities of the Company’s patient access and distribution infrastructure, the anticipated benefits of EMCITATE for patients with MCT8 deficiency, and the Company’s broader strategic plans for the development and commercialization of therapies for rare diseases. Forward-looking statements can generally be identified by words such as “expects,” “anticipates,” “intends,” “believes,” “estimates,” “plans,” “will,” “may,” “could,” “potential,” or similar expressions, although not all forward-looking statements contain these words. These statements are based on the Company’s current expectations, assumptions, and assessments as of the date of this press release and are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. Such factors include, but are not limited to: risks related to the commercial launch and market acceptance of EMCITATE in the United States; the ability to establish and maintain adequate commercial infrastructure, including distribution, patient support, and reimbursement arrangements; the timing and terms of any monetization of the Priority Review Voucher, which is subject to market conditions and the availability of interested purchasers; potential post-marketing requirements or restrictions imposed by the FDA; the ability to maintain regulatory approvals in the United States and the European Union; competition from existing or future therapies; the Company’s ability to secure adequate funding for its operations and commercial activities; and general economic, market, and business conditions. For a further description of risks and uncertainties that could affect the Company’s business and results, reference is made to the Company’s most recent annual report and other filings with relevant regulatory authorities available at www.egetis.com. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law or regulation. [1]: https://www.globenewswire.com/Tracker?data=SnGaTcY6hPV1LvBw1BfdoyV2drbr6FOD 9iZerQ2-6ZxtPmU9XdsZthA5LC69zpCSXilnJnAEAmb7dyEGd7tQBFb0ZvYbF9vZHCpkbAvrtzOszN4d zXaKSw-WHVh1RDSmrEXPnSSWlmEsCkP0OwoEiLlcXcio1Qv5-HM-kTTr3D2QLT91Ce7jX_LaD1WH8kw_ yc_SU5FeMY3iCM-Ii2i5i_VJUkVgV7ttuwSnHBRgtNFfkddVBv-DVNpxkTa32hCS9Cmt08oBacZhfEr8 s81qHKTiwj0FNeu2S7VZFGOgX3cj8kKkJ5G3FXIgHeD5jKWJW8SJL4I4m1eQAN_3jskzoWBUBmE_4mY3 oSD5kOPuCfzlhjgCHGTO5W4tnBnOCvPi8T4wQHA3WoGKBJQ6T4y9tBAhSyWQP2Zlt_Obt18OSk-pe5ij MbZJxbVCrp4Hk4j0jgbUaIWj87gv9gnCyfsFmwlNcxQ48Av-sC7R9E7JQ8ds3gvkc3eQ_9e1_xicw4yk tv9uvbjb4GE0I7cLpud1O8CPZ6by5m52KrEctkr19g45TahVJp_i1JyaB8jBMolsmTZQlZvG0Mv6_Pts gjRolyd1z06rTZJFER3IwYvaBjo3sHFpUlxzJ0EBwrRTA-1AbRmJIlnYqVsNg6wggFQ8bhz_ElEPjyGn W2XICcYUi8nJ40xxkVq9kBDErLlst8UWRltGWES-GoA_9JEOpE4agGiiyFps43xJHdzAZgpLxQWpEejG wBy5xeNAfsVYeD7G2asnblxuZKEOLDuXVa2glGQIe241k1CT1BhDCxfBKpOMjB0vz2HVqPvXAmjdxaRx cNf7BpB2E3k--BLNqHfcwVboHSru-BJHbxQ53UZ1_IDEZ7zzK97xZEEl1-vGYBvecEFZMRmGGFzQm3zC CsTXZWrEUPYw113Bdx5QP3BeNMM5xgW34wrRc_b95YJU0sIfxiOJqFSrK2xLdjAIVdUxXSebrYubtmSj 0HhPSv-qliXsf6hjPnlo0FBqQDok9r6XP9R0Xx9baSVmD4sjE1hN7vv2sZuZa-zWd2vmA6reqAOpakEn I9A9kM_OSIM6ooou [2]: https://www.globenewswire.com/Tracker?data=tAqcWtodMCst4_OwaUD3J2essLN0Dhu0 EBXVgUC07icXqiyp7TddxQahtUWfgslFH7Jh2JDkMkEbcxxOI274Ux6Cq3Ggm9nGODworzVwgqqAGuee ujGmR9rTWrmSiDH5RN0VPtnWoq5Is1-T3X0PTBbH4Dk3MVtLM7j_BX_WD3Q83XNAcuNamyt85PMvZ3sU CfS6KHKe7Dd7K6IljsyHfBKU5EoxeG4CTlDJiqpqA-1kJEoSsFn9rJ2FlEk18IzNDHZcHzg-2KfH2j0R 0h9dQHAAo667Qz86ZmrdimZSYyvcVxcsjTKVoYu6yr0fIAYSCHA5I9eTYU8UGCY-44mu19HGz-TPz1rq pfUxOnKoBjB3w02_RLCjsaHQGCmsMh31U3YlW0dpWdknZ2nSlH6geflbhep9nLlOyOxVnTg_aZFDDIkl 1dxxEAjzjjgbRCp3w6NsBpwhTGvcj2FYMPgR0gLxTPR29ez_8e9RSW2TXg3XsQ0qraBOwdy_coBUD4D3 wljFtKqGrfRRUcWOPRlKds2Uig8v2znAm-aGdI3qPFapgAMzsb-Xupns7Pe2oi5t7rAfolHUAJ2M7nCb OZqgvolLUqwpFNAEA9GYvftL1PVX4fYhAFOQAlcWsOtf4PaNRxE0X61t2Htch3vyMRdfhlBBhj_oqP8w Stw6uMVG4ZcPXIOH5F9iSMjUvj49tcbi3-kAnCI94Q0kO1IinJit_KdLB1DRZQeXdWXyFrqw3dbGz8hH W9Tf2Q-qnvI0n7fcOnx5H5Et4fE1v3cgss_W88ERZSEiZz4drgxspUaGq-qabjDxnCWE8-ypY-f_oQPR wfw9-mDVagsuWZDEF_jf5SaZbk7PPE5j15B4dcFgbQ0NmdUs4HXOqfNw9-i0RR6hzTYdsepAGhqFjDeK ZO4ThxABiY7hNeYeRDaA4c_1M8L_YSYVMGGWNM0gDrybGajn2NXw1YLyMU2C-171KGqzMJpqn3x38cUO 9VMQIzRmAD6PF_e0YdyksL3P__mWcOjrhzmsSrur8I_YJilyx5o-c0aSelBghXNWg8hX2yBFTfz4MTj5 YYEvnwv0bVh96X2kiOrTpG1VW0Qh6mNSbz2RgA== [3]: https://www.globenewswire.com/Tracker?data=2hprcYxgnri6BLd30QHW4lbR9Ibvx1F9 TyfVYok9aZiviKt2IhHq9sTw4hs-v3g7zkDQG5MfSX6i2vcjTQ8FsigGjZ9IpNdr7aMggoP14L7yno9t TIUlhw2Yqr_uvwaRhsxGF7uCzWNgwAZ9gaRDYVMBm6FJ--cjRAasp9g2S9pbdt8_H62c5HRuC0Lh1qLW IYxLM_F4BynG9UTKa2dZ_xAFAfOb5_ABVIq4zwa-TG8ugZlppOlMq_lETgXRRFnncMjRkm4YEyDt-K40 _04dxk0EV9dSMCNaXcC1aRzFGJoTnag2lD77g8l5Ec7nvGRtiYJJjE-J9iuZO-bAbQBXpbO8c0JYnIHQ -lNiYM5eD-I45GWyYBk9d2Oak83KvgEVT8Ghn-OJeSS3QOahPs6FvivG8lL0eB-w5LJ1lQDyiglpunhU 4fg462qa5yBBm2XPVwJ4uOXZdq4PzPGl3K09ueF0BFqpCoFWcJ4Kfwt3x49aDDkFj6_3MmBxIpzx7wOh lZDDg1fMkVOA4_yJpKmQ31mSADt8zc8JAaNh4Mk4kFZLbHhYugBNTOGAuxq7INOiutRLs2rC9_7X8ACu YgRufsHA4lz5_BdpneTNMcsuLYZuunduHAqXYuus2UfEvOrLfrwuuIB6Cs5JfD4NG_8QYR36IDQgEVkS 008RdutSQWkORr8r2kuMGwrmZWnFIdoV9ArdmypQbdEifJB2_LL_RkRAJF6fv40tYT1MbHb0mcFZSGtB myvKs6_aEqAApNiN5KCTA0DfOTTGLuaoc-FFP4MfWPH8-7sWW2lLilS9XTnc-wTH0iO5dZQZ2XWziEI6 r9fg-XRjA7f_KFKk_qXGYHT37_XZeDE6tmRmx4fCH1OIPIiMVkCv1dkabpW3nOVwoU_zBl978TP66x-4 bCsQ6U1Iw5C0Pp2QgIPgnB9MValmRD3UYCneNpILBq2GDuKE1TdhmgZL_crPPp5ZxlAA25PDlwhJrXrB FH47Tu56lJPqR4t0j9DgFLt06OtZ1PVQDW5ctPA-9I0BQR93SIvWxXkljxERkAAoeNeypaZNoqhgNfmD UHDLf3LdZTuQEzCS [4]: https://www.globenewswire.com/Tracker?data=s4v58NtaE0GiVwj-sLUJxCuYhn8-1ulw 7ey4W4OiurzmUTAYvsSTgzG8U6Ce36QjZj5O0Rq7e0-i6htyS1IbqzGQfk8SyUz0z7lY78O_YtuuWUHY N0COmAafpaoeC7dbwqjzrsaE-IZLIyEBo2nNnU0WC8bEY61MGl6v50WuTy_A1Qv-Gh4gHvu20lYJ_aJv _1Z-_xa8pHIYG71RMvkVODSed1j_8wU3OEgOnAVwOq51tlXyrEeThY_lLnCtc5Elqnnyy7kQP9NWqI2I APS3OhpaxJsI1iHzHXFwAMug5qBsFHlyVcHB6SYmWViY2FNtOK_bzVT91u0ufLxGgmT85pKHhRNWXNvR 4TjP1ZLw-xDV5mbTUyIkGHkYL7pZg1X9eqjM4mcc86Kce4X-WxF-HoKGwAeGCinic7ld-RhCAqNlXKS2 u0Q5H8tXsNRr8uPE1931f2Dhe70yNyHqjdAP71BoQJIvetXDMbJ0Auy0acymyLOg16HIjSsOdxWs_eZc HnLBsNJZtkeAxLbtwMjKh9d__i6Juy82A0fRcYI2gjFpQmzt3DMwR1yh5CLbzHs-oDRIMO5reV7_i71m CgxFAtMTp7o-VymbJEFdJOMVrCRokOCWbbzzOsH_yh5vU79XHHIbIqOO6EDO4uSrly0Uxk0WGirdGv01 i4UBS6G4u4BGGCr11ufA1doS2qJ9Bn3Rllwse0Vgkf5OGBDJhtYScw6O0AmQdB8OoPv9I-dDabRT4T_o NMTn5gQHNWtwvQyIDZDgYyUocUSHlSXgtgN-DFLunS7tO3KKwroF5mVgU4pFKnlHVKhOFD6oRygDGaMX 10HsH53_0SDIWMrHXAJZCl4Agk41IubWEjlvzwsWiE4Bk8EOwaZD2JwuoNg0jupAunJ03--BWFGinRIh At40wAos7BpW4iHyzH0nr3WaJHJV1_ColCyVSTb1MMFJh7PZsIRPO-HTfbjazsSFT37jk5wDogbcZQ2B 3XEo8Vjf8Zox9ROlvjyJThP3kFeRFEr3ahP-SC4Uq8wf3KVPLclGLF7LZSvlz-xDN5nhxlo6MNTgYys1 Duji4b6_aV8cU9iXSItIVZulCaTYWtJ5Md6wSybjv5CFxrc0jG-7G6X2yiFqKROHlVec4rqCchIHxVz2 7VZK0UOO7IhR44jAC2wwDqEtmmHwWsgo4osLxTlv5Nc_9KuFlxvODPnSxRX1qWUgWLYN47wdW__2Ca3Q i8_QwA== [5]: https://www.globenewswire.com/Tracker?data=GdIpW69XPK347vAilnIrSHbnc52V9-PM vf_7QTIfg-TSd_eZ5EvE8HwowDrz8-T4_EiW2xkwS8fuW2PiL0M9NdTnEeUvV1UCpZ6KQucnvfq9r2El RZwYnwvHPHt-dh2BTmY7bAnI65h63eKPj1Gz_fY9iJ2y0UXtzRhRImuvbSggPqKRPrRuPhmypxK2Db3q XNlH8WK4uX_8JeJYHWG9Y-bkVz7pitU5dOV8yab4EWBSN__mdwuiSviePOOV059AdEji6Jhjq5vUdO_H QvYjP0R6D_i7p7BKmULcFaHUrnzM56kU8kUDfFILVz0bNXlj0nsdIEchNZlV8_vyjM_DGb-pFQeTMXXN 8oz3EpKvPchuAeyyYXs8CgHIlEmQYK0kZAtIqyhoqPjlmdMIEQa_4GsuKwaPG-w4FJekOowjh-u-3Kbt G3P7Vo32RC5enpRxirOzUUCEcMdSDFtQ3vOvEPK5KYFB5_cDqer7pQmh1kPQtGcUCKH3f66n7nu3zzoH q8Dg6IBLPP5jiv6upbZCjqX89X1IQ16F3hyk0C1YbcWPVIQLtL2ncHjftOIYRuak1Td1IuQV9irI1QYj oaWbh8MjC_shdPCCP1a2afpukk2jlen9F-2m6i7qG7_cSH4A_xOvwNRoRqyRDlQcMEOGeABcY2Jd6xlI DrKhHOD4dEpNj9-e1WRZpaFC3EH2NeJNNLXVccPsCBTkFx5TBUYtqTwOyu7n_f67winXKbTAbyvumrT7 cQRqNbNesQG-uBdyxPzbdDXJMMtT3OUKw-MWoaDxx2DwfrKplycdJVIBX92Y_2iAWsNMuh5M9AUmnbrU k2OU1-4Xbg3Ql-8BDo5zFB6yZwnfShx-GJ46NFstzpaHpGA_wnD2G-wjzh1EP3KwaMmpZGsxNTrEOD3h cCRArB67f-nf_H4bYz53ENmXh6eTJVKmFQ1HzY-zdCS9QsSJbLSAreC-BiQUySng2uXqQVIVLM2RIZym bSqZ2RvDBRBmHFR2mCE7I1UdKd-_DGDDyIcB23o4_8Kdjp8im-BfBQ== [6]: https://www.globenewswire.com/Tracker?data=2hprcYxgnri6BLd30QHW4on2ywdwkNO3 qrz7F-99YSQHDg67jQrh-wUzQ3HaDQF4bPTlGtLpNFoqzfbyGHnYvoMeOSAe8mGEEgqoapruosHb4Fxu qKkZHiQb3QzBjVpyZkQUGL2kdh6ykk9jkQNwjiHjiAPqRFiUujkvShcMuwjtFOpVlVZ3QOfB0OfjOH24 O8Fi_tqwVPHMguRD4L2OW5fsvBinm2IECT6sr9iQMPEPeqZjwSaN5HagrA6Dtoa58BT3ZOdkEL5O2bB3 xlfVdj_4bvni-Nc5R_Kx2J3p0TywIVNpwjBOdaEZ8PVMMOe7yPI9M-rXwCF0_-cMMKQzX-jUVPz23pdP VSb24TMii-B-ZPmpqZ52tgpgPwGsoVGyxvHIOYru-ZBdpnonYMKIapy6RQnkh5KVEqOft0Pw0WE0_lIM letak0c1PDbSeufjwYmk-zmXIyNdydfBe5XuX8GXPaaPi5cjwSY2EpAmPE90tmandNprybNBpkj4qFOE T7pyf7U4-2PW6EeySpKA133CyMM3ezXgC9k1TOmEAo0br4S0FiXUDtz6bDM2c6m19FpHAByHAzS8lcEn 8nfVoOkF1_q2YPeRSkbUmp4WwKIxavuMald1P3cSHy_d6hGT7MR9qgC-QWCi3cp2QskXCay6AOBZkNSi 0Gn3XDQ1p4X2KBQKz3-_mlqChLuaowB0C6iElO7ZoxMd0utbIl7Xy-r5K-EzYdNiSoJX6bl6xbCZjgM_ 3feJuVf8uuuslSEqCfx0jRbistYer9dhZQJiJhyBDM0uKBvltfsFnlLaj-8aiPGXjnTsB65ttVSRDYIi IUArAy2vpKkZ8V44x2k9I7LGbs8kgfISE7aFKzNkyaRJr12MsTc9jFvkBFe2mQsLe3HJx9jxXIJHW1JG _xq8SS1J9o1A4lDd7SWeX88dGvO4ZDUa_ngVnB5bw0BysX8rgjy4cNPIUG833QtwbMRj1JRXWe7vxqMa jmt2MOOvHYbXxh62TP6rPOyZaW4fG_gglbraxhwU8I-yhKcELRnE_NqyskuB3qwb9cPF_FfscYXZfutr 4fKZq3RP7qhZoo_L [7]: https://www.globenewswire.com/Tracker?data=X2HYectQjsH3fKHqdquSMQYGP7aZ4_dE 06gnMdMrP8w1jSFJ9lQG44TbCQ62ehhWpFa6QYOMNigakhklS6i3xpjJWgNwMkEwOWndMiT3WSPj2C5U FdomxwNE4sv9joOD [8]: https://www.globenewswire.com/Tracker?data=sN7S8TrH7i8EaOSMItWgEz_swm0qhBGP VIHHTitaMLw487w2YnmtBaX6VfiUqitLQdQU_Ip7SUT7Tnovy5jSu8iyJLTKvsoFM4TFlPIpGLs= [9]: https://www.globenewswire.com/Tracker?data=MHbuatjpPJXN6titMQUS7UR80aU6wzHq wn2zzGtpIYYdu8vJlN3aidg36bGo5UMPC76jB62YemSoJE2cJpK8jQWgVbepA2oQrTlbr96rZ8k=